Evidence map›Paper›PMID 41350490›Full record

SynthesisImmunologic research2025

Efficacy and safety of natural killer cell therapy for the treatment of advanced non-small cell lung cancer: A meta-analysis and systematic review.

Zhengnan Li, Xiu'e Wang, Shaoqing Chen, Ping Zhang, Xiujuan Wang, Xinye Ni, Chunlin Mou

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Immunologic research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhengnan Li *Research & Development Department, Sino Bio-technology Co., Ltd, Tianjin, 300384, China.
Xiu'e Wang *Research & Development Department, Sino Bio-technology Co., Ltd, Tianjin, 300384, China.
Shaoqing ChenDepartment of Radiotherapy, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical University, Changzhou, 213003, China.
Ping ZhangDepartment of Anatomy, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, 300070, China.
Xiujuan WangResearch & Development Department, Sino Bio-technology Co., Ltd, Tianjin, 300384, China.
Xinye NiDepartment of Radiotherapy, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical University, Changzhou, 213003, China. nxy@njmu.edu.cn.
Chunlin MouResearch & Development Department, Sino Bio-technology Co., Ltd, Tianjin, 300384, China. mcl-bs@163.com.

Funding

West Taihu Advanced Technology Development Foundation 2022 Cultivation Project 2022-P-016
6 · The paper itself

Abstract

To evaluate the efficacy and safety of natural killer (NK) cell therapy for the treatment of advanced non-small cell lung cancer (NSCLC). Relevant studies on NK cell therapy for advanced NSCLC were collected from PubMed, Scopus, Embase and the Cochrane Library up to August, 2024. Two reviewers independently screened the articles and retrieved the data using the Cochrane risk assessment tool. Meta-analysis was conducted with R (version 4.3.1). A total of nine trials were analyzed, including five phase 2 randomized controlled and four phase 1 studies. All were medium to high quality but exhibited high performance and attrition biases. NK cell treatment doses ranged from 1×10

Indexed as

Carcinoma, Non-Small-Cell LungImmunotherapy, AdoptiveKiller Cells, NaturalLung NeoplasmsHumansTreatment OutcomeImmunotherapyNatural killer cells (NK)Non-small cell lung cancerSolid malignanciesTumor-infiltrating NK

Identifiers

PMID41350490
PMCPMC12680858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.